Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07616128 · ClinicalTrials.gov registry record · Phase 2
Study of EVO756 in Adults With Migraine
A Phase 2 study, sponsored by Evommune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 330
- Enrollment target
NCT07616128: Recruiting Phase 2 study, sponsored by Evommune.
NCT07616128 is a Phase 2 study that is actively recruiting participants, run by Evommune. The registered enrollment target is 330 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (148% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07616128, a Phase 2 study, is actively recruiting participants, sponsored by Evommune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 330 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Interventions
- DRUG Placebo
- DRUG EVO756, Dose 1
- DRUG EVO756, Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2026-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT07616128 shows while recruiting
NCT07616128 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (148% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07616128 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07616128 about?
NCT07616128 is a clinical study titled "Study of EVO756 in Adults With Migraine". This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
What is the current status of trial NCT07616128?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 330 participants. The study started on 2026-06. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07616128?
The interventions under investigation include: Placebo (DRUG), EVO756, Dose 1 (DRUG), EVO756, Dose 2 (DRUG).
Who is sponsoring clinical trial NCT07616128?
This trial is sponsored by Evommune, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07616128's enrollment target sits among peer trials
330 145th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia